RxDoctor Payments Data

Jay Futterman, MD

Ophthalmology · Lake Bluff, ILNPI 1952515645

Payments from drug & device makers

$1,566in general payments, 2019–2025

Across 46 payments — averaging $34.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$457
  • NEW World Medical,inc.$192
  • Novartis$178
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$158
  • Johnson & Johnson Surgical Vision, Inc.$137
  • Harrow Eye, LLC$130
  • plus $316 from 7 others

What the payments were for

  • Food & beverage$1,566100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,566 in reported general payments places this provider in the 50th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$194,496
Medicare patients
979
Services billed
1,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine72$90,326
XiidraLifitegrast31$42,383
LumiganBimatoprost43$28,325
Prednisolone Acetate234$10,942
SimbrinzaBrinzolamide/Brimonidine Tart22$7,548
Latanoprost433$5,746
Travoprost25$5,601
Cyclosporine23$5,386
Brimonidine Tartrate102$4,354
Ketorolac Tromethamine179$2,547
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat126$2,393
Timolol Maleate143$2,316
Bimatoprost16$2,153
Fluorometholone23$1,269
Dorzolamide Hcl56$619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$95$118,651115 claims
Bausch & Lomb Americas Inc.Xiidra$70$42,38331 claims
AlconSimbrinza$457$7,54822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Lake Bluff

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →